Cannabidiol (CBD), the main nonpsychoactive constituent of Cannabis sativa, has shown a
wide range of therapeutically promising pharmacological effects either as a sole drug or in …

The aim of this review is to present some of the recent publications on cannabidiol (CBD; 2),
a major non‐psychoactive constituent of Cannabis, and to give a general overview. Special …

Rationale Cannabidiol (CBD) products lacking regulatory approval are being used to self-
treat a myriad of conditions and for their unsubstantiated health benefits. The scientific …

States and the federal government are under growing pressure to legalize the use of
cannabis products for medical purposes in the United States. Sixteen states have legalized …

Cannabidiol (CBD) is the primary non-psychoactive chemical from Cannabis Sativa, a plant
used for centuries for both recreational and medicinal purposes. CBD lacks the psychotropic …

This Perspective of the published essential medicinal chemistry of cannabidiol (CBD)
provides evidence that the popularization of CBD-fortified or CBD-labeled health products …

Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, is attracting growing
attention in medicine for its anxiolytic, antipsychotic, antiemetic and anti-inflammatory …

Rigorous, controlled evidence for the therapeutic efficacy of CBD is lacking for many health
conditions. Possible concerns with the use of CBD as a therapeutic include the potential for …

Background: Cannabidiol is being pursued as a therapeutic treatment for multiple
conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but …

Recent advances in the research of medicinal cannabis has placed the non-intoxicating
cannabinoid cannabidiol (CBD) at the front of scientific research. The reasons behind this …